Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Aldhouse NVJ"'
Publikováno v:
In Value in Health June 2024 27(6) Supplement:S330-S331
Autor:
Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate, London, UK. Natalie.Aldhouse@Clarivate.com., Chan EKH; Janssen Global Services LLC, Raritan, NJ, USA., Al-Zubeidi T; Clinical Outcomes Assessment, Clarivate, London, UK., McKee S; Clinical Outcomes Assessment, Clarivate, London, UK., Oriol Mathieu V; Janssen Vaccines and Prevention B.V., Leiden, The Netherlands., El Khoury AC; Janssen Global Services LLC, Raritan, NJ, USA., Kitchen H; Clinical Outcomes Assessment, Clarivate, London, UK.
Publikováno v:
The patient [Patient] 2024 Jul; Vol. 17 (4), pp. 457-469. Date of Electronic Publication: 2024 Apr 06.
Autor:
Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate, London, UK. natalie.aldhouse@clarivate.com., Kitchen H; Clinical Outcomes Assessment, Clarivate, London, UK., Al-Zubeidi T; Clinical Outcomes Assessment, Clarivate, London, UK., Thursfield M; Clinical Outcomes Assessment, Clarivate, London, UK., Winnette R; Pfizer Inc, New York, NY, USA., See Tai S; Pfizer Inc, Collegeville, PA, USA., Zhu L; Pfizer Inc, Collegeville, PA, USA., Freitas C; Pfizer Inc, New York, NY, USA., Garnier N; Pfizer Inc, New York, NY, USA., Baker CL; Pfizer Inc, New York, NY, USA.
Publikováno v:
Advances in therapy [Adv Ther] 2024 Apr; Vol. 41 (4), pp. 1325-1337. Date of Electronic Publication: 2024 Feb 16.
Autor:
Abbott J; Barts and The London School of Medicine and Dentistry, London, UK., Aldhouse NVJ; Clarivate, Manchester, UK., Kitchen H; Clarivate, Manchester, UK., Pegram HC; Clarivate, Manchester, UK., Brown F; Clarivate, Manchester, UK., Macartney M; Janssen Research & Development, High Wycombe, UK., Villasis-Keever A; Janssen Global Services, LLC, Raritan, NJ, USA., Sbarigia U; Janssen Pharmaceuticals, Beerse, Belgium., Ito T; Janssen Health Economics & Market Access EMEA, High Wycombe, UK., Chan EKH; Janssen Global Services, LLC, Raritan, NJ, USA. echan15@ITS.JNJ.com., Kennedy PT; Barts and The London School of Medicine and Dentistry, London, UK. p.kennedy@qmul.ac.uk.; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Newark Street, London, E1 2AT, UK. p.kennedy@qmul.ac.uk.
Publikováno v:
Journal of patient-reported outcomes [J Patient Rep Outcomes] 2024 Mar 04; Vol. 8 (1), pp. 29. Date of Electronic Publication: 2024 Mar 04.
Autor:
Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate, London, UK. natalie.aldhouse@clarivate.com., Kitchen H; Clinical Outcomes Assessment, Clarivate, London, UK., Al-Zubeidi T; Clinical Outcomes Assessment, Clarivate, London, UK., Thursfield M; Clinical Outcomes Assessment, Clarivate, London, UK., Winnette R; Pfizer Inc, New York, NY, USA., See Tai S; Pfizer Inc, Collegeville, PA, USA., Zhu L; Pfizer Inc, Collegeville, PA, USA., Garnier N; Pfizer Inc, Collegeville, PA, USA., Baker CL; Pfizer Inc, New York, NY, USA.
Publikováno v:
Advances in therapy [Adv Ther] 2023 Dec; Vol. 40 (12), pp. 5155-5167. Date of Electronic Publication: 2023 Oct 11.
Autor:
Wyrwich KW; St. Louis, USA. kathy.wyrwich@gmail.com., Kitchen H; Clinical Outcomes Assessment, DRG (Part of Clarivate), Manchester, UK., Knight S; Clinical Outcomes Assessment, DRG (Part of Clarivate), Manchester, UK., Aldhouse NVJ; Clinical Outcomes Assessment, DRG (Part of Clarivate), Manchester, UK., Macey J; Clinical Outcomes Assessment, DRG (Part of Clarivate), Manchester, UK., Mesinkovska N; Department of Dermatology, University of California Irvine, Irvine, CA, USA., Ko JM; Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA., King BA; Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.
Publikováno v:
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2023 May; Vol. 32 (5), pp. 1319-1327. Date of Electronic Publication: 2022 Jul 12.
Autor:
Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate, UK. natalie.aldhouse@clarivate.com., Kitchen H; Clinical Outcomes Assessment, Clarivate, UK., Johnson C; Clinical Outcomes Assessment, Clarivate, UK., Marshall C; Clinical Outcomes Assessment, Clarivate, UK., Pegram H; Clinical Outcomes Assessment, Clarivate, UK., Pease S; Pfizer Inc, New York, USA., Collins S; Pfizer Inc, New York, USA., Baker CL; Pfizer Inc, New York, USA., Beaverson K; Pfizer Inc, New York, USA., Crews C; The Chandler Project, Arkansas, USA., Massey J; Evelina London Children's Healthcare, London, UK., Wyrwich KW; Pfizer Inc, New York, USA.
Publikováno v:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2022 May 07; Vol. 17 (1), pp. 182. Date of Electronic Publication: 2022 May 07.
Autor:
Macey J; Clinical Outcomes Assessment, Clarivate (formerly DRG Abacus), London, UK., Kitchen H; Clinical Outcomes Assessment, Clarivate (formerly DRG Abacus), London, UK., Aldhouse NVJ; Clinical Outcomes Assessment, Clarivate (formerly DRG Abacus), London, UK., Edson-Heredia E; Eli Lilly and Company, Indianapolis, IN, USA., Burge R; Eli Lilly and Company, Indianapolis, IN, USA.; Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Prakash A; Eli Lilly and Company, Indianapolis, IN, USA., King BA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA., Mesinkovska N; Department of Dermatology, University of California Irvine, Irvine, CA, USA.
Publikováno v:
The British journal of dermatology [Br J Dermatol] 2022 May; Vol. 186 (5), pp. 849-860. Date of Electronic Publication: 2022 Feb 25.
Autor:
Macey J; Clinical Outcomes Assessment, DRG Abacus (Part of Clarivate), Manchester, UK., Kitchen H; Clinical Outcomes Assessment, DRG Abacus (Part of Clarivate), Manchester, UK., Aldhouse NVJ; Clinical Outcomes Assessment, DRG Abacus (Part of Clarivate), Manchester, UK., Burge RT; Eli Lilly and Company, Indianapolis, IN, USA.; Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA., Edson-Heredia E; Eli Lilly and Company, Indianapolis, IN, USA. eheredia@lilly.com., McCollam JS; Eli Lilly and Company, Indianapolis, IN, USA., Isaka Y; Medical Development Unit, Eli Lilly Japan K.K., Kobe, Japan., Torisu-Itakura H; Medical Development Unit, Eli Lilly Japan K.K., Kobe, Japan.
Publikováno v:
Dermatology and therapy [Dermatol Ther (Heidelb)] 2021 Apr; Vol. 11 (2), pp. 433-447. Date of Electronic Publication: 2021 Jan 10.
Autor:
Wyrwich KW; Patient-Focused Outcomes Center of Expertise, Eli Lilly and Company, Indianapolis, IN, USA., Kitchen H; Clinical Outcomes Assessment, DRG Abacus, Manchester, UK., Knight S; Clinical Outcomes Assessment, DRG Abacus, Manchester, UK., Aldhouse NVJ; Clinical Outcomes Assessment, DRG Abacus, Manchester, UK., Macey J; Clinical Outcomes Assessment, DRG Abacus, Manchester, UK., Nunes FP; Lilly Bio-Medicines, Eli Lilly and Company, Indianapolis, IN, USA., Dutronc Y; Lilly Bio-Medicines, Eli Lilly and Company, Indianapolis, IN, USA., Mesinkovska N; University of California Irvine Dermatology Clinical Research Center, Irvine, CA, USA., Ko JM; Stanford Dermatology, Stanford University School of Medicine, Stanford, CA, USA., King BA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Publikováno v:
The British journal of dermatology [Br J Dermatol] 2020 Dec; Vol. 183 (6), pp. 1065-1072. Date of Electronic Publication: 2020 May 26.